Halozyme Therapeutics (HALO) Tops Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
Revenue Growth %: +36.2%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +36.2%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.02, $0.03 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $63.7 million versus the consensus estimate of $58.95 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Barclays says AI trade is maturing, favors greater diversification
- Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
